These side effects may perhaps lead to ongoing abuse and undermine any endeavours to deal with an ongoing opioid use disorder (OUD).[19][twenty] This substantial overlap concerning fatal and nonfatal doses implies that there may be no "Protected" blood focus of xylazine.[four] Because of a lack of distinct evidence regarding the pharmacokinetic